RESALIS THERAPEUTICS
Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche
RESALIS THERAPEUTICS
Address:
Torino, Piemonte, Italy
Country:
Italy
Status:
Active
Total Funding:
6 M EUR
Similar Organizations
Alchemab Therapeutics
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
C4 Therapeutics
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
Finpiemonte
Finpiemonte investment in Seed Round - Resalis Therapeutics
Claris Ventures
Claris Ventures investment in Seed Round - Resalis Therapeutics
Club degli Investitori
Club degli Investitori investment in Seed Round - Resalis Therapeutics
More informations about "Resalis Therapeutics"
Resalis Therapeutics – Tackling metabolic disorders with non …
With its deep expertise in non-coding RNA and lipid metabolism, Resalis Therapeutics is advancing RES-010 as a safe, effective, and disease-modifying therapy, offering sustained …See details»
Resalis Therapeutics – Tackling metabolic disorders with non …
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease.See details»
Resalis Therapeutics - Crunchbase Company Profile & Funding
Resalis Therapeutics changes the way metabolic diseases are treated by targeting a key regulator of pathways that contribute to obesity and fatty liver disease. RES-010, the company's flagship …See details»
Our Team - Resalis Therapeutics
Resalis Therapeutics is led by an experienced team with significant pharmaceutical industry, scientific and RNA medicine expertise. The company is also supported by a visionary Board as well as trusted advisors.See details»
About Us – Resalis Therapeutics
Resalis is developing RES-010, a novel treatment for obesity and fatty liver disease. With its lead program, Resalis is opening a new therapeutic opportunity as a stand-alone treatment for obesity or to synergize with the current …See details»
Resalis Therapeutics Company Profile 2024: Valuation, …
Developer of non-coding RNA-based therapeutics designed to address metabolic disorders such as obesity and fatty liver disease. The company's platform leverages expertise in lipid metabolism and RNA modalities, enabling doctors …See details»
Resalis Therapeutics - LinkedIn
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease.See details»
Torino-based Resalis raises €10 million Series A to …
Jan 4, 2024 · Resalis Therapeutics, an Italian company tackling metabolic disorders with non-coding RNAs, announced the closing of a €10 million Series A financing round led by Sunstone Life Science Ventures with participation from …See details»
Resalis Therapeutics Announces Seed Financing of €10 …
Feb 22, 2023 · TORINO, Italy-- ( BUSINESS WIRE )-- Resalis Therapeutics today announced its completion of the seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic...See details»
Resalis Therapeutics - Funding, Financials, Valuation & Investors
Resalis Therapeutics is funded by 6 investors. Sanofi and Claris Ventures are the most recent investors. in funding over 4 rounds. Their latest funding was raised on Oct 28, 2024 from a …See details»
Resalis Therapeutics receives €10M for RNA-based …
Feb 24, 2023 · Resalis Therapeutics has completed a seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases.See details»
Resalis Therapeutics - VentureRadar
Develops RNA-targeted therapeutics for metabolic diseases, focusing on obesity and fatty liver disease, with a leading program, RES-010, aimed at disease-modifying impacts.See details»
Resalis takes aim at ‘master regulator of metabolism’
Feb 22, 2023 · Italy-based Resalis launched today with €10 million ($10.7 million) to develop therapies targeting non-coding RNA to treat metabolic diseases. Non-coding RNA is RNA that …See details»
Investors - Resalis Therapeutics
Resalis’ approach is supported by our trusted investors. Cookie Policy; Privacy Policy; Resalis Therapeutics srl Via Ettore de Sonnaz 19 10121, Torino, ItalySee details»
Resalis Therapeutics Raises €10 Million Series A to Complete First ...
Jan 4, 2024 · RES-010 is a non-coding RNA-based compound designed to provide a disease-modifying approach in obesity with longer-lasting weight reduction and the ability to extend …See details»
Resalis Therapeutics Raises €10 Million Series A to Complete First ...
Jan 4, 2024 · Resalis has a deep understanding of the field of ncRNAs and RNA-targeted therapeutics in human health and metabolic disorders. The company’s lead candidate, RES …See details»
Resalis Therapeutics gets equity investment from Sanofi
Oct 29, 2024 · Italian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 …See details»
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
Oct 28, 2024 · Resalis Therapeutics is dedicated to developing RNA-based therapies that tackle the root causes of complex metabolic disorders. With its deep expertise in non-coding RNA …See details»
Resalis takes aim at noncoding RNA | C&EN Global Enterprise
According to the team at Resalis Therapeutics , it’s also a hot target. The Italy-based company launched Feb. 22 with €10 million ($10.7 million) to develop therapies targeting noncoding …See details»
Resalis Therapeutics | The Pharmaletter
Nov 5, 2024 · Resalis Therapeutics An Italian biotech company developing RNA-based therapies that tackle the root causes of complex metabolic disorders. Resalis' lead investigational …See details»